Doximity, Inc. (DOCS) Acquires Pathway Medical to Supercharge AI Clinical Tools

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Doximity, Inc. is one of them.

Doximity, Inc. (NYSE:DOCS) remains a leading healthcare technology stock, leveraging AI-driven tools and strategic acquisitions to strengthen its position in the medical sector. The company operates a cloud-based professional network for U.S. clinicians, offering secure telemedicine, collaboration, and workflow solutions.

Recently, DOCS completed the acquisition of Pathway Medical, an AI-powered clinical reference platform. The integration enhances Doximity’s flagship DoxGPT tool, providing instant, verified access to medical data, peer-reviewed research, and context-aware AI responses within daily clinical workflows. Pathway’s AI model scored 96% on the U.S. Medical Licensing Exam benchmark, underscoring the corporation’s commitment to clinical quality and innovation.

DOCS also expanded its offerings with Doximity Scribe, a free ambient AI scribe that automates clinical documentation and reduces after-hours administrative work.

Doximity, Inc. (DOCS) Acquires Pathway Medical to Supercharge AI Clinical Tools

Doximity, Inc. (NYSE:DOCS)’s last quarter, ending June 30, 2025, saw revenue climb 15% year-over-year, reaching $145.9 million, which exceeded analyst forecasts. The company delivered non-GAAP earnings per share (EPS) of $0.36. User engagement and product adoption surged, especially in new AI scribe and workflow tools.

While we acknowledge the risk and potential of DOCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DOCS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.